Twenty-three phase I and II studies were included in the review (n=463).
Carcinoembryonic antigen (14 studies, 281 patients).
The 4 studies reporting complete response rates reported complete response in 0, 5 and 10% of patients. The 9 studies reporting partial response rates reported partial response in 0 to 20% of patients. The 7 studies reporting stable disease reported this in between 12 and 54% of patients. The one study using pre-targeted radioimmunotherapy did not report on the effectiveness.
Tumour-associated glycoprotein 72 (4 studies, 60 patients).
Three studies reported stable disease in 22 to 25% of patients; the fourth study reported no response in any patients.
A33 (2 studies, 44 patients).
Two trials reported a mixed response in 13% and 5% of patients, respectively.
Epithelial cellular adhesion molecule (2 studies, 53 patients).
One of the 2 studies reported stable disease in 38% of patients; the other study using pre-targeted radioimmunotherapy showed partial response in 8% of patients and stable disease in 16% of patients.
Colon-specific antigen P (1 study, 25 patients). The identified study did not report on the effectiveness.